Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,400,096
  • Shares Outstanding, K 257,245
  • Annual Sales, $ 182,240 K
  • Annual Income, $ -356,390 K
  • 60-Month Beta 1.16
  • Price/Sales 13.57
  • Price/Cash Flow N/A
  • Price/Book 5.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.28
  • Number of Estimates 6
  • High Estimate -0.24
  • Low Estimate -0.34
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +28.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.25 +49.28%
on 03/16/20
10.84 -13.93%
on 03/26/20
+0.19 (+2.08%)
since 03/03/20
3-Month
6.25 +49.28%
on 03/16/20
11.29 -17.36%
on 02/13/20
+0.15 (+1.63%)
since 01/03/20
52-Week
6.25 +49.28%
on 03/16/20
14.61 -36.16%
on 04/08/19
-4.73 (-33.64%)
since 04/03/19

Most Recent Stories

More News
Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FOLD : 9.33 (-2.91%)
Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees

Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that the Company...

FOLD : 9.33 (-2.91%)
Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass

Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.

REGN : 493.32 (-1.09%)
FOLD : 9.33 (-2.91%)
ADRO : 2.54 (+1.20%)
NBRV : 0.5147 (-2.76%)
SmarTrend Watching for Potential Rebound in Shares of Amicus Therapeut After 5.40% Loss

Amicus Therapeut (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $8.76 to a high of $9.55. Yesterday, the shares fell 5.4%, which took the trading range below the 3-day low of $8.88...

FOLD : 9.33 (-2.91%)
Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -34.62% and 2.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

FOLD : 9.33 (-2.91%)
Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates

2019 Galafold Revenue Nearly Doubled to $182.2M

FOLD : 9.33 (-2.91%)
Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference

Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference in Boston, MA on Tuesday,...

FOLD : 9.33 (-2.91%)
Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FOLD : 9.33 (-2.91%)
Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 2, 2020 at 8:30 a.m. ET to discuss financial results for the full...

FOLD : 9.33 (-2.91%)
Amicus Therapeut Rises 2.82% on Heavy Volume: Watch For Potential Pullback

Amicus Therapeut (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $10.44 to a high of $10.82. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high...

FOLD : 9.33 (-2.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade FOLD with:

Business Summary

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in...

See More

Key Turning Points

2nd Resistance Point 9.92
1st Resistance Point 9.63
Last Price 9.33
1st Support Level 9.09
2nd Support Level 8.85

See More

52-Week High 14.61
Fibonacci 61.8% 11.42
Fibonacci 50% 10.43
Fibonacci 38.2% 9.45
Last Price 9.33
52-Week Low 6.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar